Study of Fluoxetine in Patients With Depersonalization Disorder

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to:

1) Determine the effects of fluoxetine in the treatment of depersonalization disorder, 2) Assess the durability of treatment response in these patients, 3) Assess the improvement in psychiatric disability in these patients, and 4) Assess the effects of comorbid Axis I disorders (depression, social phobia, panic/anxiety, obsessive-compulsive disorder) and Axis II personality disorders on treatment outcome in these patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Institute of Mental Health (NIMH)
• Collaborator: Icahn School of Medicine at Mount Sinai
• Treatments: Fluoxetine

Criteria

Inclusioin Criteria:

• Meets DSM-IV criteria for depersonalization disorder in the last month

Exclusion Criteria:

• Prior or concurrent bio- or chemotherapy or

• Use of any of the following within 2 weeks prior to study entry: antipsychotics, anticonvulsants, stimulants, barbiturates, lithium, benzodiazepines, or antidepressants

• Use of MAO inhibitors or investigational drugs within 4 weeks prior to study entry

• History of fluoxetine use at a dose of 10 mg or more for at least 6 weeks duration

• Hematologic, hepatic, renal, cardiovascular, pulmonary, metabolic, endocrine, systemic, or gastrointestinal disease

• History of mental disorders

• Current substance abuse

• Current eating disorder

• Current clinically unstable suicidal ideation

• Unstable medical illness

• Clinically unstable

• Clinically important abnormalities in lab tests or physical exams

• History of seizure disorders or abnormal electroencephalogram

• Hypersensitivity or severe side effects to fluoxetine

• Pregnancy or breast-feeding. Women of child-bearing potential must use effective contraception